Nectero Therapeutics

Executive Summary

Nectero Therapeutics is a privately held, pre-clinical stage company headquartered in Scottsdale, Arizona, focused on developing innovative therapies for cardiovascular diseases through advanced drug delivery technologies. Founded in 2018, the company is led by a multidisciplinary management team and supported by a board of directors and renowned vascular surgeons. Nectero's platform aims to address significant unmet needs in vascular interventions, potentially improving outcomes for patients with conditions such as aneurysms or atherosclerosis. While specific pipeline details are limited, the company's approach leverages targeted delivery to enhance efficacy and reduce systemic side effects. As a pre-clinical entity, Nectero is in the early stages of advancing its lead candidate toward first-in-human studies, with ongoing preclinical activities expected to yield critical data in the near term. The company's progress will depend on successful completion of IND-enabling studies and securing partnerships or funding to support clinical translation.

Upcoming Catalysts (preview)

• Q4 2026Release of preclinical proof-of-concept data60% success
• H1 2027Filing of Investigational New Drug (IND) application40% success
• Q2 2027Announcement of strategic partnership or licensing deal35% success